Humana Inc. (NYSE:HUM) Receives Consensus Rating of “Hold” from Brokerages

Humana Inc. (NYSE:HUM) has been given a consensus recommendation of “Hold” by the twenty-four analysts that are covering the stock, MarketBeat reports. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $285.68.

A number of equities research analysts have commented on the stock. Wells Fargo & Company cut their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th.

Humana Price Performance

Shares of NYSE HUM opened at $255.77 on Monday. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a market cap of $30.80 billion, a P/E ratio of 25.71, a PEG ratio of 2.05 and a beta of 0.56. The company has a 50 day moving average of $269.41 and a 200 day moving average of $289.61. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.38%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is currently 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Several hedge funds have recently bought and sold shares of HUM. Dodge & Cox lifted its stake in Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Norges Bank purchased a new stake in shares of Humana during the 4th quarter valued at about $416,202,000. Pzena Investment Management LLC raised its position in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its position in shares of Humana by 435.8% during the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after buying an additional 893,637 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.